<DOC>
	<DOCNO>NCT01616524</DOCNO>
	<brief_summary>The purpose study determine 24 week treatment Pegylated Interferon Lambda plus Ribavirin 12 week treatment Pegylated Interferon Lambda plus Ribavirin Daclatasvir safe effective treatment hepatitis C compare 24 week treatment Pegylated Interferon Alfa-2a plus Ribavirin</brief_summary>
	<brief_title>Safety Efficacy Study Pegylated Interferon Lambda With Without Daclatasvir , Compared Pegylated Interferon Alfa , Plus Ribavirin Subjects With Hepatitis C Genotype 2 3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Chronic hepatitis C , Genotype 2 3 Na√Øve prior antiHCV therapy Infected HCV Genotype 2 3 Positive Hepatitis B surface antigen ( HBsAg ) , Human immunodeficiency virus1 ( HIV1 ) /HIV2 antibody screen Evidence liver disease HCV Active substance abuse Evidence decompensated cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>